Related Experiment Video
Updated: Jul 9, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Infliximab in recalcitrant generalized pustular arthropatic psoriasis
Vasco Vieira Serrão1, Andréa Martins, M João Paiva Lopes
1Dermatology Department, Hospital dos Capuchos, Alameda Santo António dos Capuchos, 1150 - 314 Lisboa, Portugal. vvsferreira@netcabo.pt
European Journal of Dermatology : EJD
|December 19, 2007
Summary
Infliximab rapidly treated severe generalized pustular psoriasis and joint pain in a patient resistant to other therapies. This biologic therapy offers significant relief and improved quality of life for difficult psoriasis cases.
Area of Science:
- Dermatology
- Immunology
- Rheumatology
Background:
- Generalized pustular psoriasis (GPP) is a severe, unstable inflammatory skin condition.
- GPP presents with erythema, sterile pustules, fever, and systemic symptoms.
- Infliximab, an anti-TNFalpha monoclonal antibody, is approved for psoriasis treatment.
Observation:
- A male patient with a history of psoriatic arthritis developed GPP.
- The patient's condition was resistant to acitretin, methotrexate, and corticosteroids.
- He was treated with infliximab due to disease severity and treatment resistance.
Findings:
- Infliximab demonstrated a very rapid response in both skin and joint symptoms.
- Complete skin lesion clearing occurred by week 12.
- Significant improvement in articular symptoms and quality of life was observed.
- No recurrence was noted at 8 months with infliximab maintenance therapy.
Implications:
- Infliximab shows rapid efficacy in recalcitrant generalized pustular psoriasis.
- The biologic agent effectively manages associated psoriatic arthritis symptoms.
- This treatment offers a promising therapeutic option for severe, treatment-resistant psoriasis and arthritis, enhancing patient quality of life.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...